Navigation Links
The Astellas European Foundation Winner of Transplantation Grant 2011 Announced

GLASGOW, Scotland, September 7, 2011 /PRNewswire/ --

The Astellas European Foundation is delighted to announce the winner of the 2011 Transplantation Grant:

Dr Christian Toso of the University of Geneva, Switzerland

Last evening, the University's team, led by Dr Toso, received the grant of US$ 300,000 to support work on their project entitled 'Towards a tailored immuno-suppression after liver transplantation for hepatocellular carcinoma' at the Astellas European Foundation Award presentation.

Dr Ayad Abdulahad, Astellas European Foundation Trustee and Vice President Medical Affairs and Health Economics for Astellas Pharma Europe Ltd. commented, "We received many entries of a very high standard which covered a broad range of topics across Europe.  In the face of very strong competition the Jury chose Dr Toso's research based on its potential impact on clinical practice.  The team's aim is to tailor immunosuppressive strategy for individual patients with hepatocellular carcinoma. It is very exciting and, in the future, their results could possibly be applied to other cancers."

At the Award Presentation Event in Glasgow, UK, the Astellas European Foundation emphasised their continued and long term commitment to research and development in the field of transplant medicine.

Dr Toso said, "We thank the Astellas European Foundation for its generous support. Although liver transplantation is the most efficient treatment for patients with early  unresectable hepatocellular carcinoma, some 10% of recipients still experience recurrence after transplantation. The aim of our study is to define the ideal immunosuppression strategy, both clearing cancer cells and preventing rejection. Such a study has the potential to better tailor immunosuppression after liver transplantation for cancer, improve outcomes and qualify some currently excluded patients with more advanced HCCs for transplantation."

The Astellas European Foundation is a registered charity. It was established in 2005 with the  goal of providing support for programmes and activities that contribute to the advancement of an increasingly healthy society. The Astellas European Foundation Transplantation Grant supports basic medical and related scientific programmes which contribute to advancements in transplant medicine.  The winner of the grant was chosen by a Jury that includes independent European transplantation leaders.

Notes to Editors

About The Astellas European Foundation

The Astellas European Foundation is a registered charity, established in 2005, with the long-term goal of providing support for programmes and activities that contribute to the advancement of an increasingly healthy society. The Astellas European Foundation is registered with the Charity Commission for England and Wales with number 1036344.

About Astellas Pharma Europe Ltd.

Astellas Pharma Europe Ltd., located in the UK, is a European subsidiary of Tokyo-based Astellas Pharma Inc. Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. The organisation is committed to becoming a global company by combining outstanding R&D and marketing capabilities and continuing to grow in the world pharmaceutical market. Astellas Pharma Europe Ltd. is responsible for 21 affiliate offices located across Europe, the Middle East, and Africa, an R&D site, and three manufacturing plants. The company employs approximately 4,000 staff across these regions.

SOURCE Astellas European Foundation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Astellas and Medivation Enter Into Worldwide Agreement to Co-Develop and Co-Commercialize MDV3100 for the Treatment of Prostate Cancer
2. Ironwood and Astellas Announce Japan Licensing Agreement for Linaclotide
3. Emerging Agents from Theravance/Astellas, Johnson & Johnson/Basilea and Forest/Astrazeneca/Takeda Will Drive Modest Growth in the MRSA Drug Market Through 2018
4. Ambit Biosciences and Astellas Enter Strategic Partnership to Research, Develop and Commercialize FLT3 Kinase Inhibitors in Multiple Indications
5. Astellas Announces Full Slate of Independent Director Nominees for Election at OSI Pharmaceuticals 2010 Annual Stockholders Meeting
6. Astellas Announces Successful Completion of Initial Tender Offer for Shares of OSI and Announces Subsequent Offer Period
7. Agensys, an Affiliate of Astellas, Announces Initiation of Phase I Clinical Trial of AGS-16M8F for Renal Cancer
8. Astellas Awards Scholarships to 12 Transplant Recipients and Donors Who Embody Hope, Courage and Achievement
9. Astellas Mobilizes 1,300+ Employees in the Americas to Participate in First Annual Changing Tomorrow Day
10. Although NeurogesX/Astellass Qutenza is Only Approved for Postherpetic Neuralgia, Surveyed U.S. Physicians are Likely to Prescribe It for All Neuropathic Pain Types
11. Astellas Announces Retirement of Donald Rice and Appointment of Sef Kurstjens as CEO and President of Agensys, Inc.
Post Your Comments:
(Date:6/24/2016)... The Academy of Managed Care Pharmacy (AMCP) ... would allow biopharmaceutical companies to more easily share health ... and coverage decisions, a move that addresses the growing ... The recommendations address restrictions in the sharing of ... label, a prohibition that hinders decision makers from accessing ...
(Date:6/24/2016)... , June 24, 2016 According ... by Type (Standard Pen Needles, Safety Pen Needles), Needle ... GLP-1, Growth Hormone), Mode of Purchase (Retail, Non-Retail) - ... This report studies the market for the forecast period ... reach USD 2.81 Billion by 2021 from USD 1.65 ...
(Date:6/23/2016)... -- MedSource announced today that it has selected Datatrial,s ... choice.  This latest decision demonstrates MedSource,s commitment to ... by offering a state-of-the-art electronic data capture (EDC) ... the EDC platform of choice in exchange for ... long been a preferred EDC platform by our ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now ... of Final Cut Pro X," said Christina Austin - CEO of Pixel Film Studios. ... Final Cut Pro X users can now reveal the media of their split ...
(Date:6/27/2016)... ... 27, 2016 , ... A revolution is underway. Brooklyn-based ... experience for the millions of people who require these medical transport services annually. ... through the use of technology. Now, SmartEMS has put forth an industry-changing app ...
(Date:6/26/2016)... , ... June 26, 2016 , ... On June 10-11, ... of the 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, ... the city’s history as home to some of the world’s leading providers of cereal ...
(Date:6/26/2016)... ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer ... through a fitness app. The fitness app plans to fix the two major problems leading ... a one size fits all type program , They don’t eliminate all the ...
(Date:6/25/2016)... ... , ... Austin residents seeking Mohs surgery services, can now turn to Dr. ... Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include ... in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn ...
Breaking Medicine News(10 mins):